Phase 2 Ovarian Cancer Trial, Not Yet Recruiting NCT07652073 Sponsor: Danatlas Pharmaceuticals Co., Ltd Condition: Ovarian Cancer
Back to Ovarian Cancer

Phase 2 Ovarian Cancer Trial, Not Yet Recruiting

NCT07652073
Not Yet Recruiting Phase 2

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People who are willing and able to sign a written consent form agreeing to participate
  • People who are at least 18 years old
  • People who have been diagnosed with epithelial ovarian cancer, confirmed by laboratory testing of tissue or fluid samples
  • People who have a BRCA1 or BRCA2 gene mutation, or whose cancer has tested positive for a feature called HRD (homologous recombination deficiency)
  • People whose cancer has not responded to standard treatments, or who are unable to tolerate standard treatments
  • People who have received no more than five previous rounds of cancer treatment
  • People who have at least one tumour that can be measured on a scan
  • People whose general physical condition is rated 0, 1, or 2 on a standard scale used by doctors to measure how well a person is able to carry out daily activities (confirm with trial site)
  • People whose bone marrow, liver, kidneys, and other organs are functioning at a level that meets the trial's requirements (confirm with trial site)
  • Women who could become pregnant must have a negative blood pregnancy test before starting the trial

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who have received certain chemotherapy or targeted therapy tablets or capsules within 2 weeks or 5 half-lives before starting the trial (confirm with trial site)
  • People who have received a biological cancer therapy (such as an antibody treatment) within 4 weeks before starting the trial
  • People who have had major surgery within 4 weeks before starting the trial
  • People who have previously been treated with a type of drug called a PARG inhibitor
  • People whose cancer did not respond adequately to a previous maintenance therapy using a type of drug called a PARP inhibitor
  • People who have cancer that has spread to the brain or spinal cord
  • People who have significant heart or blood vessel disease (confirm with trial site)
  • People who have an active infection that cannot be controlled and requires antibiotic treatment through a drip or a hospital stay
  • People who are still experiencing side effects from previous cancer treatment that have not improved to a mild level (grade 1 or lower)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 17 July 2026

Contact this trial

Phone: +86-10-67803200

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Phase 2
Sponsor
Danatlas Pharmaceuticals Co., Ltd
Registry
ClinicalTrials.gov
Start date
15 June 2026
Est. completion
30 November 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Objective response rate ( ORR )

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 17 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov